Viridian Therapeutics, Inc. VRDN Business Segments — Other items
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s business segments — other items.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s business segments — other items?
- Viridian Therapeutics, Inc. (VRDN) reported business segments — other items of -$11.29M in Q1 2026.
- How has Viridian Therapeutics, Inc.'s business segments — other items changed year-over-year?
- Viridian Therapeutics, Inc.'s business segments — other items decreased by 63.4% year-over-year, from -$6.91M to -$11.29M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s business segments — other items?
- Over 3 years (2022 to 2025), Viridian Therapeutics, Inc.'s business segments — other items has grown at a 50.6% compound annual growth rate (CAGR), from -$6.2M to -$21.18M.
- What does business segments — other items mean?
- This metric captures miscellaneous income or expense items that do not fall under core research, development, or administrative categories within the business segment. It often includes non-recurring or peripheral financial activities that impact the segment's bottom line. Tracking these items helps isolate core operational performance from incidental financial events.